We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Huperzine A (from Huperzia serrata)
Acetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
What the evidence says
Huperzine A doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1991–2026 with a typical study size of 100 participants.
Based on 55 studies · 9 meta-analyses · 11 RCTs · 51,080 total participants
Confidence
High confidenceWhat the studies found
By outcome
Scored moderate because multiple meta-analyses show MMSE/ADL benefit in Alzheimer's and vascular dementia, but reviewers consistently flag poor trial quality, a well-controlled US phase II trial missed its primary endpoint, and healthy-adult nootropic data are absent.
14 randomised trials
79% were about Huperzine A in an audit of 14 of them
Every randomised or controlled trial of Huperzine A indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
8 trials ongoing or recruiting · 9 completed on ClinicalTrials.gov
Registered trials show research momentum for Huperzine A, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Oct 2026
Huperzine A is a compound from Chinese club moss (Huperzia serrata) used in traditional Chinese medicine. It inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine, raising levels of this memory-related neurotransmitter.
Most clinical evidence comes from Chinese trials in Alzheimer's disease and vascular dementia: meta-analyses suggest cognitive (MMSE/ADL) benefit, but reviewers consistently flag the poor methodological quality of the underlying studies, and a well-controlled US phase II trial found no benefit on its primary endpoint.
Evidence in mild cognitive impairment is judged insufficient, and data in healthy people seeking nootropic effects is essentially absent.
Blocks the enzyme that breaks down acetylcholine
Protects neurons from damage
May promote new brain cell growth
How Huperzine A works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Studied for this population; consult doctor
Huperzine A is itself a cholinesterase inhibitor, so it duplicates these medicines and can cause excess cholinergic effects. Do not add it without the prescriber's agreement.
Opposing effects - anticholinergics antagonize huperzine A's cholinergic action, reducing effectiveness of either
Additive slowing of heart rate (bradycardia) from combined cholinergic and beta-blocking effects; monitor
Additive cholinergic effects may increase risk of nausea, salivation, bradycardia, and other cholinergic excess
Tip: Reduce dose; take with food
Tip: Avoid evening dosing
Tip: Reduce dose
Huperzine A has an evidence score of 6/10 — moderate evidence based on 55 indexed studies, including 9 meta-analyses. Acetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality. Representative study: PMID 24639880.
The commonly studied dose of Huperzine A is 50-200mcg twice daily. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Huperzine A is in the morning. Taking it with food is preferred. Huperzine A is a potent, selective, and reversible acetylcholinesterase inhibitor derived from Huperzia serrata (Chinese club moss).
Huperzine A has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. The most commonly reported side effects are vivid dreams, nausea, muscle twitching. Use caution if any of these apply to you: Heart conditions (can slow heart rate); Asthma/COPD (can increase bronchial secretions); GI ulcers (increases gastric acid).
Phosphatidylserine
Too few graded studiesKey brain membrane phospholipid that facilitates neurotransmitter release, memory formation, and post-exercise cortisol reduction.
Multivitamin
Too few graded studiesNutritional insurance that fills micronutrient gaps. In the large COSMOS trial, a daily multivitamin improved memory and slowed cognitive decline in older adults — but it did not reduce total cancer, cardiovascular disease, or mortality.
Sage
Too few graded studiesA Mediterranean herb with rosmarinic acid and salvianolic compounds that support cognitive function, menopausal symptom relief, and metabolic health through antioxidant and cholinergic mechanisms.
Caffeine
Probably helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — an umbrella review of 21 meta-analyses found it ergogenic for endurance, strength and power.
Explore: Best supplements for Focus, Memory & MoodBest supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 55 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research